Pages

Showing posts with label DNA tests. Show all posts
Showing posts with label DNA tests. Show all posts

Thursday, 29 April 2021

With DNA tests for $3, Chinese startup Genebox raises tens of millions

 There are already a number of companies in China offering genetic tests direct to consumers. Investors are betting big on Genebox, which offers unbelievably low prices, and plans to develop critical technology locally.

If you give Genebox a tube of spit and as little as $3, the company promises to tell you the best strategy for you to lose weight and care for your skin, your risks of developing diabetes or cancer, and who your ancestors are. The Beijing-based startup is one of the over 100 companies in China’s direct-to-consumer DNA test industry, which is expected to see $405 million in sales by 2022.


Genebox announced (in Chinese) this Monday that it had raised “tens of millions in U.S. dollars” in a Series A+ round of financing led by Centurium Capital.

  • Founded in 2018, Genebox previously netted around 136 million yuan ($21 million) in its angel round led by the leading drug retail chain Dashenlin Pharmaceutical, and the Series A led by the consumer- and healthcare-focused Centurium Capital.

Genetics is a core focus of China’s push to become a global leader in healthcare, science, and technology. With government encouragement, direct-to-consumer DNA-testing companies like Genebox and its domestic rival, 23Mofang, provide extremely affordable and accessible gene analysis services.

  • As of 2019, more than 2.2 million Chinese had sent test tubes of spit to private companies to have their DNA analyzed. The number has surged since 2017, when the National Development and Reform Commission listed genetic testing in the 13th Five-Year-Plan’s strategy for the biological industry, according to Shenzhen-based Qianzhan Industry Research Institute (in Chinese).
  • While most DNA tests are conducted through healthcare providers for medical purposes, direct-to-consumer genetic testing is typically marketed directly to younger consumers through the internet and social media, with the selling points being historical information about ancestry and predictions about future health.

Chinese genetic testers offer almost unbelievably low prices

Chengdu-based 23Mofang was one of the first direct-to-consumer genetic testing startups in China, founded in 2015 after the founder, Zhōu Kūn 周坤, was inspired by America’s 23andMe and supported by cash infusions from six rounds of fundraising totaling 160 million yuan ($24.5 million).

  • By 2017, 23Mofang had brought the price of DNA testing down to 499 yuan ($76), one-fourth of the cost from other providers when the service debuted in the Chinese market in 2013.
  • Genebox entered the market in 2018 and took the starting price even lower, to 19.9 yuan ($3). Lǐ Zhì 李智, Genebox’s founder and CEO, said the company attempts to attract users to send their DNA samples through the low basic package price, and they can pay additional fees to unlock other data and analysis.
  • GeneBox only ships test kits to mainland China addresses, while 23Mofang said it also serves overseas Chinese nationals. In the U.S., 23andMe’s basic test is currently selling for $79. The American company ships to Hong Kong, but does not offer services for mainland China residents.


To localize the genetic testing procedure and further lower costs, Genebox earlier this year announced (in Chinese) it had made China’s first independently developed microarray, a biochip that measures the expression levels of a large number of genes at the same time, breaking into the upstream technology market currently dominated by America’s Illumina.

  • Li said Genebox is mass-producing the new biochips and aims to replace all imported microarrays by next spring.


Privacy concerns are rising as direct-to-consumer genetic testing companies gain more popularity in China.

  • Genebox says in the terms of service that it will not share any personal information with third parties without user consent, but exceptions include complying with certain laws and regulations or if “forcefully” required by the government.
  • Beijing retains the right to access data held by all Chinese companies for national security, public health, and social interest reasons, according to China’s Personal Information Security Specification.
  • Genebox said it may also share user data with its subsidiaries, affiliated organizations, or third-party research institutions for purposes such as scientific and medical research, as well as new product development. 23Mofang has an even longer list of scenarios where it may use genetic data without consent, including news reporting and system maintenance.
  • Both Genebox and 23Mofang said they will eliminate personal identity information from the data before sharing it with third parties for research purposes. “Personal information after anonymization is not personal information,” 23Mofang says in its terms of service (in Chinese). “23Mofang has the right to mine, analyze, and utilize the anonymized user database.”

https://supchina.com/2020/12/11/with-dna-tests-for-3-chinese-startup-genebox-raises-tens-of-millions/

Tuesday, 4 August 2020

'Life saving' 90-minute tests for coronavirus and flu to be rolled out from next week

Tests for coronavirus and flu that can provide results in 90 minutes are to be rolled out across hospitals, care homes and laboratories from next week.
EVENING STANDARD
Health Secretary Matt Hancock described the breakthrough as "life-saving" and said the "on-the-spot" tests will help prevent the spread of Covid-19 this winter.
The Department of Health said that the "rapid" swab and DNA tests will help clinicians and NHS Test and Trace staff distinguish between coronavirus and other seasonal illnesses.
This could prevent patients from unnecessarily self-isolating for an illness that is not Covid-19.
Nearly half a million new LamPORE swab tests will be available from next week across adult care settings and laboratories. Millions more of the tests, supplied by Oxford Nanopore, are set to be rolled out later in the year.
Meanwhile, thousands of DNA test machines, which have already been used in eight London hospitals and can analyse nose swabs, will be rolled out across NHS hospitals from September.
“Millions of new rapid coronavirus tests will provide on-the-spot results in under 90 minutes, helping us to break chains of transmission quickly," said Mr Hancock.
The DNA and swab tests aim to help clinicians differentiate between coronavirus and other seasonal illnesses (AP)
“The fact these tests can detect flu as well as Covid-19 will be hugely beneficial as we head into winter, so patients can follow the right advice to protect themselves and others.
“I am hugely grateful for the excellent work done by DnaNudge and Oxford Nanopore to push forward these life-saving innovations in coronavirus testing.”
Some 5,000 machines, supplied by DnaNudge, will provide 5.8 million tests in the coming months, said the Department of Health.
NHS launches ‘Let’s Get Back’ campaign to encourage testing through NHS Test and Trace
Professor Chris Toumazou, co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London, said: “The DnaNudge team worked with incredible speed and skill during the peak of the pandemic to deliver this highly accurate, rapid Covid-19 test, which requires absolutely no laboratory or pipettes and can be deployed anywhere with a direct sample-to-result in around just over an hour.”
Gordon Sanghera, CEO of Oxford Nanopore, said: “LamPORE has the potential to deliver a highly effective and, crucially, accessible global testing solution, not only for Covid-19 but for a range of other pathogens.”
The new tests were announced hours after the DHSC was forced to deny that it had abandoned its pledge to regularly test care home residents through the summer.
According to a leaked memo from the Government’s adult social care testing director, seen by the Sunday Times, Professor Jane Cummings wrote to local authority leaders to inform them that “previously advised timelines for rolling out regular testing in care homes” were being altered because of “unexpected delays”.
Regular testing of residents and staff was meant to have started on July 6 but will now be pushed back until September 7 for older people and those with dementia, the PA news agency understands.
A DHSC spokeswoman confirmed there were issues with “asymptomatic re-testing”.
Additional reporting by PA Media.

Wednesday, 9 October 2019

Pancreatic Cancer: You Can Spot This Killer Before It’s Too Late

Genetic tests can help determine your risk—and possibly save your life…

Diane M. Simeone, MD, an internationally recognized surgeon and scientist, the associate director for translational research at Perlmutter Cancer Center at NYU Langone Health and director of its Pancreatic Cancer Center in New York City. 


Date July 1, 2019   Publication Bottom Line Health





CANCER PREVENTION

Pancreatic Cancer: You Can Spot This Killer Before It’s Too Late

Pancreatic cancer is often lethal because it is rarely detected in early stages. Now, life-saving screening can monitor your risk. Read on…


Pancreatic cancer is a frightening disease because it’s usually diagnosed only when it’s reached an advanced, all-too-often lethal stage. But it doesn’t have to be that way. 
Everyone knows about screening guidelines for colon cancer and breast cancer, but few are aware that screening tests for pancreatic cancer also are available. Recognizing the key risk factors for this malignancy will help you and your doctor decide whether such tests are appropriate for you or a loved one.
When a pancreatic cancer is found via a screening program, there is an 80% to 90% chance that the tumor can be removed, and up to 30% to 35% of those individuals will live for five or more years. 
However, when a pancreatic cancer is found in a person who has not been regularly screened and he/she has already developed symptoms (such as abdominal or back pain, weight loss, nausea and/or jaundice), there is only a 15% chance that it can be removed. This lack of early detection, along with the need for improved therapies, has resulted in a persistently low overall survival rate of 9% for pancreatic cancer patients.
Here’s how to spot pancreatic cancer before it’s too late…

Know Your Risk Factors

The first step to staying ahead of pancreatic cancer is knowing how to assess your risk factors. Your risk is higher if you have any of the following…
• Two or more relatives with pancreatic cancer, including one first-degree relative (parent, sibling or child). 
• A first-degree relative who developed pancreatic cancer before age 50.
• An inherited genetic syndrome  linked to pancreatic cancer such as Lynch syndrome, which is also associated with colorectal cancer…or BRCA mutations, which predispose a person to breast, ovarian and prostate cancers. 
Note: People of Ashkenazi Jewish (Central and Eastern Europe) descent aren’t the only ones who can have BRCA mutations. Though less common, individuals of Norwegian, Swedish, Italian and other ethnic groups have been found to also carry certain BRCA mutations. 
Other factors that increase your risk for pancreatic cancer…
• Long-standing type 2 diabetes (more than five years), which increases pancreatic cancer risk by twofold. Note: New-onset diabetes—especially when weight loss instead of weight gain appears—may be an early sign of pancreatic cancer.
• Chronic pancreatitis, which can be caused by heavy use of alcohol (usually four or more drinks a day), increases risk for pancreatic cancer by about threefold.  
• Personal history of another type of cancer, such as breast or colon cancer or melanoma. 
• Smoking. About 25% of all pancreatic cancer cases are associated with smoking.
• Age. Most people with pancreatic cancer are diagnosed after age 45.
• Gender. Men are slightly more at risk than women. 
• Obesity. People with a body mass index (BMI) of 30 or more are 20% more likely to develop pancreatic cancer.
• Workplace exposure to certain chemicals. Research has found significant links between workplace exposure to chemicals, such as pesticides, asbestos, benzene and chlorinated hydrocarbons, and increased risk for pancreatic cancer.
• Diet. Eating a diet high in processed meats and/or red meat has been linked to increased risk for pancreatic cancer. For every 50 g of processed meat consumed daily (roughly the equivalent of one hot dog or four strips of bacon), risk for pancreatic cancer increases by 19%. The increased risk linked to red meat consumption is less significant but also present—especially in men.
Important: An easy-to-use online Pancreatic Cancer Risk Assessment tool (Find-PanCancer-Early.org) can help determine your risk level based on your answers to a few brief questions about your personal and family medical history. You also can work with your own physician to do a thorough family history if you’re more comfortable with that approach.

Next Steps

If you have any risk factors for pancreatic cancer that are controllable, take immediate action. For example, stop smoking…reduce or eliminate alcohol if you are a heavy drinker…lose weight if you’re overweight…and avoid diabetes or treat it if you’ve already been diagnosed with this condition.  
Meanwhile, if you have a family history of pancreatic cancer, talk to your doctor about getting your DNA examined through germline genetic testing, a blood test that looks for specific hereditary mutations in your cells and can help determine your risk. The cost of germline testing has plummeted in recent years, and there are validated tests that check a panel of gene mutations that can be performed for as little as $250. In individuals with a family history of pancreatic cancer, germline testing is typically covered by insurance.
Guidelines published in 2018 in Journal of Clinical Oncology recommend that all patients with pancreatic cancer consider having germline testing. Individuals with a strong family history of pancreatic cancer also are advised to undergo testing and screening. 
At the multidisciplinary Pancreatic Cancer Center at the NYU Perlmutter Cancer Center, we found that 15% of pancreatic cancer patients have a germline mutation (also known as a “hereditary mutation”) that increased the patient’s risk of developing the disease, even if a strong family history wasn’t present. 
Knowing whether such a hereditary, or germline, mutation is present in a pancreatic cancer patient may change the treatment strategy…and have implications for testing siblings and children who might also be at higher risk. 
Genetic counseling will help you understand the test results and decide whether it’s appropriate to consider enrolling in a screening program run by specialists in pancreatic cancer. To locate a certified genetics counselor, consult the National Society of Genetic Counselors at NSGC.org.
If an individual is deemed to be high risk, annual imaging of the pancreas is recommended. Two types of tests are used—a pancreatic MRI/MRCP (a special type of MRI)…and an endoscopic ultrasound (EUS).
We usually start with the MRI/MRCP and then check with an EUS the next year, alternating the exams each year. The two tests are complementary and examine the pancreas in slightly different ways. Insurance should cover these tests. 
The MRI is noninvasive. With EUS, an upper endoscopy is performed, passing a thin scope down the esophagus into the stomach and the first part of the small intestine after sedation is given (much like a colonoscopy, but no prep is needed). The scope has an ultrasound probe at the end, and the pancreas can be readily visualized, as it is next to the stomach.
Both tests have only very minor risks, but it’s important that the screening be done in a multidisciplinary clinic where there’s collaboration among various health-care providers, such as genetic counselors, gastroenterologists, pancreatic surgeons, radiologists and social workers as well as a tumor board, where this team of experts, along with oncologists, meets to discuss each patient’s unique situation. Pancreatic cancer is a complicated disease, and decision-making in high-risk individuals is best done with an experienced team guiding your care.
Important: Even with a genetic mutation linked to pancreatic cancer, most people will not get the disease. But with an increased risk, it is crucial to know that screening can be an effective strategy to combat pancreatic cancer. I tell my patients, knowledge is power. As we do a better job in identifying individuals at risk, we will be much better positioned to shift the disease from the advanced state to one in which many more patients have easier-to-treat, surgically resectable disease.
With a concerted effort in early detection (and prevention), along with the development of more effective therapies and clinical trial strategies, it is likely that we will see a change in survival in pancreatic cancer patients in the coming years—and it’s about time. 
This is a rapidly moving field, so ask questions and seek information from doctors who are at the forefront of the research. 

Getting the Best Care



The Pancreatic Cancer Action Network (PanCan.org) is a patient-advocacy group that serves as a resource for finding a high-quality pancreatic cancer center. It’s the driving force behind Precision Promise, a multicenter “adaptive” clinical trial initiative that allows multiple novel therapies to be evaluated alongside standard-of-care approaches to speed the development of new treatments.
Other excellent resources: Rolfe Pancreatic Cancer Foundation (RolfeFoundation.org), a nonprofit dedicated to early diagnosis of pancreatic cancer, research that aims to cure the disease and resources for patients and their families…and Project Purple (ProjectPurple.org), another nonprofit group that funds research to defeat pancreatic cancer and supports patients and their families.
https://bottomlineinc.com/health/cancer-prevention/pancreatic-cancer-you-can-spot-this-killer-before-its-too-late